ACTG175 {BART} | R Documentation

## AIDS Clinical Trials Group Study 175

### Description

ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.

### Usage

    data(ACTG175)

### Format

A data frame with 2139 observations on the following 27 variables:

`pidnum`

  patient's ID number

`age`

  age in years at baseline

`wtkg`

  weight in kg at baseline

`hemo`

  hemophilia (0=no, 1=yes)

`homo`

  homosexual activity (0=no, 1=yes)

`drugs`

  history of intravenous drug use (0=no, 1=yes)

`karnof`

  Karnofsky score (on a scale of 0-100)

`oprior`

  non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)

`z30`

  zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)

`zprior`

  zidovudine use prior to treatment initiation (0=no, 1=yes)

`preanti`

  number of days of previously received antiretroviral therapy

`race`

  race (0=white, 1=non-white)

`gender`

  gender (0=female, 1=male)

`str2`

  antiretroviral history (0=naive, 1=experienced)

`strat`

  antiretroviral history stratification (1='antiretroviral naive', 2='> 1 but ≤q 52 weeks of prior antiretroviral therapy', 3='> 52 weeks')

`symptom`

  symptomatic indicator (0=asymptomatic, 1=symptomatic)

`treat`

  treatment indicator (0=zidovudine only, 1=other therapies)

`offtrt`

  indicator of off-treatment before 96\pm5 weeks (0=no,1=yes)

`cd40`

  CD4 T cell count at baseline

`cd420`

  CD4 T cell count at 20\pm5 weeks

`cd496`

  CD4 T cell count at 96\pm5 weeks (=`NA` if missing)

`r`

  missing CD4 T cell count at 96\pm5 weeks (0=missing, 1=observed)

`cd80`

  CD8 T cell count at baseline

`cd820`

  CD8 T cell count at 20\pm5 weeks

`cens`

  indicator of observing the event in `days`

`days`

  number of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50 (ii) an event indicating progression to AIDS, or (iii) death.

`arms`

  treatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine, 3=didanosine).

### Details

The variable `days` contains right-censored time-to-event observations. The data set includes the following post-randomization covariates: CD4 and CD8 T cell count at 20\pm5 weeks and the indicator of whether or not the patient was taken off-treatment before 96\pm5 weeks.

### References

Hammer SM, et al. (1996), "A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter.", New England Journal of Medicine, 335:1081–1090.

[Package BART version 2.5 Index]